The Journal of Experimental Medicine
Rockland Immunochemicals for Research
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 4 February 2002. doi:10.1084/jem.20011149
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 102K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferlazzo, G.
Right arrow Articles by Münz, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferlazzo, G.
Right arrow Articles by Münz, C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2002/2/343/ $5.00
The Journal of Experimental Medicine, Volume 195, Number 3, February 4, 2002 343-351


Original Article

Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells

Guido Ferlazzo1, Ming L. Tsang2, Lorenzo Moretta3,4, Giovanni Melioli1, Ralph M. Steinman2 and Christian Münz2

1 Laboratorio di Immunoterapia Cellulare, Unità di Immunologia, Istituto Nazionale per la Ricerca sul Cancro, 16132 Genova, Italy
2 Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021
3 Istituto Giannina Gaslini, 16147 Genova, Italy
4 Dipartimento di Medicina Sperimentale (DIMES), Università di Genova, 16132 Genova, Italy

Address correspondence to Guido Ferlazzo, Laboratorio di Immunoterapia Cellulare, Unità di Immunologia, Istituto Nazionale per la Ricerca sul Cancro, Centro di Biotecnologie Avanzate, Largo Rosanna Benzi, 10, 16132 Genova, Italy. Phone: 39-010-573-7453; Fax: 39-010-573-7462; E-mail: ferlazzo{at}cba.unige.it

During the innate response to many inflammatory and infectious stimuli, dendritic cells (DCs) undergo a differentiation process termed maturation. Mature DCs activate antigen-specific naive T cells. Here we show that both immature and mature DCs activate resting human natural killer (NK) cells. Within 1 wk the NK cells increase two– to fourfold in numbers, start secreting interferon (IFN)-{gamma}, and acquire cytolytic activity against the classical NK target LCL721.221. The DC-activated NK cells then kill immature DCs efficiently, even though the latter express substantial levels of major histocompatibility complex (MHC) class I. Similar results are seen with interleukin (IL)-2–activated NK cell lines and clones, i.e., these NK cells kill and secrete IFN-{gamma} in response to immature DCs. Mature DCs are protected from activated NK lysis, but lysis takes place if the NK inhibitory signal is blocked by a human histocompatibility leukocyte antigen (HLA)-A,B,C–specific antibody. The NK activating signal mainly involves the NKp30 natural cytotoxicity receptor, and not the NKp46 or NKp44 receptor. However, both immature and mature DCs seem to use a NKp30 independent mechanism to act as potent stimulators for resting NK cells. We suggest that DCs are able to control directly the expansion of NK cells and that the lysis of immature DCs can regulate the afferent limb of innate and adaptive immunity.

Key Words: natural killer cells • dendritic cells • NCR • immune regulation • NKp30


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS